KRAS G12C Lung Adenocarcinoma in a 42-Year-Old Woman

Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.

Assess whether the initial therapy aligned with standard guidelines based on disease stage.

Discuss the role of molecular profiling and KRAS G12C testing in guiding treatment decisions of this case.

Address the challenges and recommended approaches for managing the patient’s untreated brain metastases.

Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.

Analyze the appropriate washout period when switching between KRAS inhibitors.

Highlight key findings in the KRYSTAL-7 trial.

Overview of side effects and management when combining these agents.

Discuss emerging data and therapies to optimize future treatment.